Amarin's EN101 meets Phase IIa endpoint

Amarin Corp. plc (NASDAQ:AMRN) said top-line data from a Phase IIa study to treat myasthenia gravis showed that EN101 met the primary endpoint of significantly reducing Quantitative Myasthenia Gravis ...